EnGeneIC Pty Ltd.

EnGeneIC Launches Phase I/IIa Trial of Novel EDV Nanocell Therapy for EGFR-Positive Advanced Cancers

10 days ago

• EnGeneIC has dosed the first patient in a Phase I/IIa trial evaluating EGFR-targeted EDV nanocells carrying PNU-159682 plus immune-stimulating adjuvant for advanced EGFR-positive solid tumors. • The innovative trial targets difficult-to-treat cancers including NSCLC, mesothelioma, pancreatic cancer, and triple-negative breast cancer in patients who have exhausted standard treatment options. • The multi-center study will expand from Sydney's Mater Hospital to Frankston Hospital in Victoria and internationally to Curie Oncology in Singapore, potentially offering new hope for patients with poor-prognosis cancers.

BioCina Partners with EnGeneIC to Manufacture Novel Nanocell Cancer Therapy

8 months ago

• BioCina and EnGeneIC have formed a strategic partnership to scale up production of EnGeneIC's proprietary EDV™ nanocell technology, which delivers targeted cancer treatments with reduced systemic toxicity. • The collaboration involves technology transfer, process scale-up, and GMP batch manufacturing of Antibody-Nanocell Drug Conjugates (ANDCs) that can overcome drug resistance while stimulating anti-cancer immune responses. • EnGeneIC is currently advancing to Phase IIa clinical trials in Australia and the USA for patients with intractable cancers, including metastatic pancreatic cancer, with BioCina providing end-to-end manufacturing support.